Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 20.44
DXCM's Cash to Debt is ranked higher than
60% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. DXCM: 20.44 )
Ranked among companies with meaningful Cash to Debt only.
DXCM' s 10-Year Cash to Debt Range
Min: 0.4  Med: 14.40 Max: No Debt
Current: 20.44
Equity to Asset 0.79
DXCM's Equity to Asset is ranked higher than
78% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. DXCM: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
DXCM' s 10-Year Equity to Asset Range
Min: -0.63  Med: 0.71 Max: 0.92
Current: 0.79
-0.63
0.92
F-Score: 7
Z-Score: 96.06
M-Score: -3.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -7.69
DXCM's Operating margin (%) is ranked lower than
57% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. DXCM: -7.69 )
Ranked among companies with meaningful Operating margin (%) only.
DXCM' s 10-Year Operating margin (%) Range
Min: -2272.81  Med: -93.13 Max: -8.29
Current: -7.69
-2272.81
-8.29
Net-margin (%) -8.00
DXCM's Net-margin (%) is ranked lower than
56% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.26 vs. DXCM: -8.00 )
Ranked among companies with meaningful Net-margin (%) only.
DXCM' s 10-Year Net-margin (%) Range
Min: -2147.42  Med: -113.45 Max: -8.64
Current: -8
-2147.42
-8.64
ROE (%) -19.21
DXCM's ROE (%) is ranked lower than
64% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.76 vs. DXCM: -19.21 )
Ranked among companies with meaningful ROE (%) only.
DXCM' s 10-Year ROE (%) Range
Min: -60568.63  Med: -73.89 Max: -19.97
Current: -19.21
-60568.63
-19.97
ROA (%) -14.29
DXCM's ROA (%) is ranked lower than
62% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.65 vs. DXCM: -14.29 )
Ranked among companies with meaningful ROA (%) only.
DXCM' s 10-Year ROA (%) Range
Min: -178.43  Med: -68.09 Max: -14.59
Current: -14.29
-178.43
-14.59
ROC (Joel Greenblatt) (%) -48.58
DXCM's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. DXCM: -48.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DXCM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3333.88  Med: -731.48 Max: -50.89
Current: -48.58
-3333.88
-50.89
Revenue Growth (3Y)(%) 43.80
DXCM's Revenue Growth (3Y)(%) is ranked higher than
95% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. DXCM: 43.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DXCM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 14.65 Max: 103.1
Current: 43.8
0
103.1
EBITDA Growth (3Y)(%) -35.00
DXCM's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. DXCM: -35.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DXCM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -28.05 Max: 0.6
Current: -35
0
0.6
EPS Growth (3Y)(%) -23.90
DXCM's EPS Growth (3Y)(%) is ranked lower than
75% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. DXCM: -23.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DXCM' s 10-Year EPS Growth (3Y)(%) Range
Min: -40.1  Med: -19.80 Max: 37.1
Current: -23.9
-40.1
37.1
» DXCM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DXCM Guru Trades in Q2 2014

Joel Greenblatt 8,033 sh (New)
RS Investment Management 538,660 sh (+8.58%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ron Baron 1,348,572 sh (-0.41%)
Mario Gabelli 70,500 sh (-0.70%)
» More
Q3 2014

DXCM Guru Trades in Q3 2014

Joel Greenblatt Sold Out
Ron Baron 1,345,322 sh (-0.24%)
Mario Gabelli 66,000 sh (-6.38%)
RS Investment Management 433,460 sh (-19.53%)
» More
Q4 2014

DXCM Guru Trades in Q4 2014

Jim Simons 269,343 sh (New)
Joel Greenblatt 9,915 sh (New)
RS Investment Management 535,254 sh (+23.48%)
Ron Baron 1,340,731 sh (-0.34%)
Mario Gabelli 51,600 sh (-21.82%)
» More
Q1 2015

DXCM Guru Trades in Q1 2015

Joel Greenblatt Sold Out
Ron Baron 1,338,407 sh (-0.17%)
Mario Gabelli 50,800 sh (-1.55%)
RS Investment Management 354,260 sh (-33.81%)
Jim Simons 69,343 sh (-74.25%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DexCom Inc

Top Insider Sells Highlight: Dexcom Inc.
CEO, 10% Owner of Dexcom Inc (NASDAQ:DXCM) Terrance H Gregg sold 23,893 shares on 08/21/2014 at an average price of $44.36. The total transaction amount was $1,059,893. Read more...

Ratios

vs
industry
vs
history
Forward P/E 172.41
DXCM's Forward P/E is ranked lower than
93% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. DXCM: 172.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 44.98
DXCM's P/B is ranked lower than
98% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. DXCM: 44.98 )
Ranked among companies with meaningful P/B only.
DXCM' s 10-Year P/B Range
Min: 3.88  Med: 14.81 Max: 209.25
Current: 44.98
3.88
209.25
P/S 22.77
DXCM's P/S is ranked lower than
87% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.22 vs. DXCM: 22.77 )
Ranked among companies with meaningful P/S only.
DXCM' s 10-Year P/S Range
Min: 6.36  Med: 15.00 Max: 1058.5
Current: 22.77
6.36
1058.5
PFCF 704.98
DXCM's PFCF is ranked lower than
100% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.75 vs. DXCM: 704.98 )
Ranked among companies with meaningful PFCF only.
DXCM' s 10-Year PFCF Range
Min: 496.58  Med: 612.46 Max: 753.29
Current: 704.98
496.58
753.29
POCF 222.63
DXCM's POCF is ranked lower than
99% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.69 vs. DXCM: 222.63 )
Ranked among companies with meaningful POCF only.
DXCM' s 10-Year POCF Range
Min: 155.77  Med: 209.47 Max: 1503.33
Current: 222.63
155.77
1503.33
EV-to-EBIT -302.69
DXCM's EV-to-EBIT is ranked lower than
263% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.37 vs. DXCM: -302.69 )
Ranked among companies with meaningful EV-to-EBIT only.
DXCM' s 10-Year EV-to-EBIT Range
Min: -297.1  Med: -13.60 Max: -1.6
Current: -302.69
-297.1
-1.6
Current Ratio 3.95
DXCM's Current Ratio is ranked higher than
66% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. DXCM: 3.95 )
Ranked among companies with meaningful Current Ratio only.
DXCM' s 10-Year Current Ratio Range
Min: 1.96  Med: 4.43 Max: 23.47
Current: 3.95
1.96
23.47
Quick Ratio 3.45
DXCM's Quick Ratio is ranked higher than
66% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. DXCM: 3.45 )
Ranked among companies with meaningful Quick Ratio only.
DXCM' s 10-Year Quick Ratio Range
Min: 1.82  Med: 4.14 Max: 23.47
Current: 3.45
1.82
23.47
Days Inventory 54.97
DXCM's Days Inventory is ranked higher than
61% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. DXCM: 54.97 )
Ranked among companies with meaningful Days Inventory only.
DXCM' s 10-Year Days Inventory Range
Min: 23.53  Med: 49.97 Max: 73.69
Current: 54.97
23.53
73.69
Days Sales Outstanding 51.50
DXCM's Days Sales Outstanding is ranked higher than
69% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.88 vs. DXCM: 51.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXCM' s 10-Year Days Sales Outstanding Range
Min: 16.96  Med: 50.07 Max: 71.25
Current: 51.5
16.96
71.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 157.28
DXCM's Price/Net Cash is ranked lower than
98% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.85 vs. DXCM: 157.28 )
Ranked among companies with meaningful Price/Net Cash only.
DXCM' s 10-Year Price/Net Cash Range
Min: 4.94  Med: 27.30 Max: 166
Current: 157.28
4.94
166
Price/Net Current Asset Value 63.86
DXCM's Price/Net Current Asset Value is ranked lower than
91% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.23 vs. DXCM: 63.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DXCM' s 10-Year Price/Net Current Asset Value Range
Min: 4.88  Med: 18.35 Max: 53.03
Current: 63.86
4.88
53.03
Price/Tangible Book 47.18
DXCM's Price/Tangible Book is ranked lower than
97% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.15 vs. DXCM: 47.18 )
Ranked among companies with meaningful Price/Tangible Book only.
DXCM' s 10-Year Price/Tangible Book Range
Min: 4.7  Med: 13.76 Max: 154.75
Current: 47.18
4.7
154.75
Price/Median PS Value 1.52
DXCM's Price/Median PS Value is ranked lower than
77% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. DXCM: 1.52 )
Ranked among companies with meaningful Price/Median PS Value only.
DXCM' s 10-Year Price/Median PS Value Range
Min: 0.54  Med: 0.98 Max: 45.27
Current: 1.52
0.54
45.27
Earnings Yield (Greenblatt) (%) -0.30
DXCM's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. DXCM: -0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DXCM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -0.6  Med: 0.00 Max: 0
Current: -0.3
-0.6
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 367 512 674
EPS($) -0.06 0.49 1.01
EPS without NRI($) -0.06 0.49 1.01

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:DC4.Germany,
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company's SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc. Jul 20 2015 
Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM Jul 14 2015 
Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc. Jul 13 2015 
Dexcom’s Smart Glucose Monitoring System Receives FDA Approval Jan 27 2015 
Top Insider Sells Highlight: Dexcom Inc. Aug 22 2014 
DexCom Reports $1 Million Insider Buy Mar 12 2013 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2010 
DexCom Inc. Reports Operating Results (10-Q) May 05 2010 
DexCom Inc. Reports Operating Results (10-Q) Nov 04 2009 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2009 

More From Other Websites
Four Medical Picks With Healthy Earnings Outlooks Aug 04 2015
DexCom Announces Upcoming Conference Presentations Jul 30 2015
DexCom Announces Upcoming Conference Presentations Jul 30 2015
Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc. Jul 20 2015
CORRECTING and REPLACING DexCom Schedules Second Quarter 2015 Earnings Release and Conference Call... Jul 16 2015
CORRECTING and REPLACING DexCom Schedules Second Quarter 2015 Earnings Release and Conference Call... Jul 16 2015
DexCom Schedules Second Quarter 2015 Earnings Release and Conference Call for August 5, 2015 at 4:30... Jul 16 2015
Coverage initiated on Dexcom by Robert W. Baird Jul 08 2015
Dexcom and Nick Jonas Raise Their Voices for Diabetes Awareness Jun 11 2015
Dexcom and Nick Jonas Raise Their Voices for Diabetes Awareness Jun 11 2015
DexCom's (DXCM) Follow CGM App Now on Android Devices - Analyst Blog Jun 03 2015
DEXCOM INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Jun 02 2015
Dexcom® Announces Follow App is Now Available for Android Devices Jun 02 2015
Dexcom® Announces Follow App is Now Available for Android Devices Jun 02 2015
DexCom Announces Upcoming Conference Presentations May 29 2015
DexCom Announces Upcoming Conference Presentations May 29 2015
DexCom Hits 52-Week High, Robust Pipeline Key Catalyst - Analyst Blog May 28 2015
4 Biotech Stocks Could Have Big Upside Before Russell Index Changes May 12 2015
DexCom (DXCM) Q1 Loss Wider Than Expected; Shares Fall - Analyst Blog Apr 30 2015
After-hours buzz: Yelp, Glu Mobile, Baidu & more Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK